Bartosz Hudzik/LinkedIn
May 23, 2026, 16:42
Bartosz Hudzik: Bleeding Risk Alone Should Not Determine Treatment Intensity
Bartosz Hudzik, Associate Profesor at Medical University of Silesia, shared his post a post on X, adding:
“HBR has become synonymous with antithrombotic de-escalation.
Yet bleeding risk alone should not determine treatment intensity.
Many AF, MI, PCI patients classified as HBR remain ischemic-risk dominant, underscoring the need for personalized rather than algorithmic therapy.”
Bartosz Hudzik shared a post on X:
“At EuroPCR 2026, we show that many HBR, AF, MI, PCI patients remain ischemic-risk dominant despite high bleeding risk.
In selected patients, triple antithrombotic therapy may still provide net clinical benefit”
Other posts featuring Bartosz Hudzik on Hemostasis Today.
-
Oct 6, 2026, 09:56Anitha Narayanamurthy: A Possible Missing Link in Unexplained Blood Test Abnormalities
-
Oct 6, 2026, 09:46Francois Roubille: Biomarkers and Long-Term Prognosis After Revascularised STEMI
-
Oct 6, 2026, 09:20EAS Rare Lipid Disorder Course – Advancing Lipid Disorder Education – European Atherosclerosis Society
-
Oct 6, 2026, 09:12Fionnuala Ní Áinle: Lisa Ryan’s First Thrombocalc VTE Research Report
-
Oct 6, 2026, 09:02David McIntosh: Preventable Maternal and Newborn Deaths – The Urgent Need for Action
-
Oct 6, 2026, 08:55Konstantin Yenkoyan: CAR-T, GLP-1 or Orexin – Who Will Take the 2026 Nobel?
-
Oct 6, 2026, 08:39Emily Bury: Putting Patients at the Centre of VTE Care
-
Oct 6, 2026, 07:44Carolina Moreira Ponce: Thrombosis Month – Why Prevention Starts With Risk Assessment
-
Oct 6, 2026, 07:03Laila Ahmed: Stroke Imaging – A Practical Radiology Approach